Fantastic result for the company and shareholders today. However...

Fantastic result for the company and shareholders today. However tomorrow is another day (which is going to be interesting to see) and our eyes should now turn to when the CLI trial will commence. This is a much bigger fish to target compared to GVHD, " the demand for global critical limb ischemia treatment market was USD 3,129 million in 2018 and is expected to generate USD 5,390 million by 2025, at a CAGR of 8.1% between 2019 and 2025."
https://www.globenewswire.com/news-release/2019/07/09/1880040/0/en/Global-Critical-Limb-Ischemia-Treatment-Market-Worth-USD-5-390-Million-By-2025-Zion-Market-Research.html

The company has slated a 2019 commencement for a Phase 2 trial (https://www.cynata.com/critical-limb-ischemia) which at the moment (maybe for not much longer now) is planned to be funded in house (https://www.cynata.com/company-faqs). If the P2 trial is completed before being licensed out I would expect a larger royalty percentage for shouldering the early risk. Even at 2018 rates a 10% slice is AUD$450 million pa. Philby's $4 billion mc predictions may not be as silly as some people on here assume and this is even before we start talking about the even bigger fish of OA.

Here's hoping Killian has been a busy boy and the rest of the team use todays announcement as motivation to keep the foot to the floor!

GLTAH